CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...